A61P 31/16
For influenza or rhinoviruses
Official title: for influenza or rhinoviruses
A61P31/16 (For influenza or rhinoviruses) appears on 4,285 US grants and 7,240 published applications in this corpus.
Search patents in A61P- Granted patents
- 4,285
- Published applications
- 7,240
- Assignees
- 2,603
- Inventors
- 11,815
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 3 | 0 |
| 1981 | 1 | 0 |
| 1982 | 2 | 0 |
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 4 | 0 |
| 1986 | 2 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 4 | 0 |
| 1993 | 5 | 0 |
| 1994 | 3 | 0 |
| 1995 | 6 | 0 |
| 1996 | 15 | 0 |
| 1997 | 22 | 0 |
| 1998 | 21 | 0 |
| 1999 | 24 | 0 |
| 2000 | 34 | 0 |
| 2001 | 53 | 10 |
| 2002 | 53 | 64 |
| 2003 | 66 | 141 |
| 2004 | 39 | 174 |
| 2005 | 47 | 201 |
| 2006 | 62 | 168 |
| 2007 | 80 | 232 |
| 2008 | 93 | 272 |
| 2009 | 119 | 353 |
| 2010 | 124 | 518 |
| 2011 | 185 | 511 |
| 2012 | 223 | 488 |
| 2013 | 259 | 366 |
| 2014 | 303 | 370 |
| 2015 | 272 | 299 |
| 2016 | 285 | 348 |
| 2017 | 281 | 322 |
| 2018 | 237 | 299 |
| 2019 | 256 | 302 |
| 2020 | 202 | 293 |
| 2021 | 188 | 255 |
| 2022 | 149 | 274 |
| 2023 | 149 | 336 |
| 2024 | 145 | 311 |
| 2025 | 157 | 207 |
| 2026 | 100 | 126 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Mutant influenza B/Victoria lineage virus hemagglutinin proteins6 Oct 2026US 12,752,001 B2ModernaTX, Inc.
- Lipidated FLIPr and uses thereof in vaccine6 Oct 2026US 12,752,003 B2National Health Research Institutes
- Vaccines, vaccine priming, and antigen dose sparing22 Sep 2026US 12,741,022 B2Adjuvance Technologies, Inc.
- Self-assembled peptide nanorods and uses thereof15 Sep 2026US 12,735,458 B2DéVeloppement Mondial Nanotech Inc.
- Use of membrane inhibitors to enhance vaccine development against enveloped viruses8 Sep 2026US 12,728,161 B2Cornell University
- Production method8 Oct 2026US 2026/0306577 A1AG IP Company Pty Ltd
- Hexahydro[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine deuterated derivative, pharmaceutical composition thereof, preparation method therefor, and anti-influenza use thereof8 Oct 2026US 2026/0308174 A1Changsha Jingyi Pharmaceutical Technology Co., Ltd
- Nanoparticle-based influenza virus vaccines and uses thereof1 Oct 2026US 2026/0295028 A1The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Novel inhibitors of pikfyve and methods using same1 Oct 2026US 2026/0297108 A1Tme Therapeutics Inc.
- Influenza virus vaccines24 Sep 2026US 2026/0284174 A1Glaxosmithkline Biologicals SA
Most cited
By later US patents
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Dinucleoside phosphinates and their pharmaceutical compositions508US 5,466,677 ACiba-Geigy Corporation · 1995
- Antimicrobial compositions comprising a benzoic acid analog and a metal salt342US 6,294,186 B12001
- Molecules with extended half-lives, compositions and uses thereof342US 7,083,784 B2MedImmune, LLC · 2006
- Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1328US 7,595,048 B2Ono Pharmaceutical Co., Ltd. · 2009